VEGFA and age-related macular degeneration: In a nonrandomized, open-label phase 2a study in exudative AMD, 43 anti-VEGF therapy naive patients received 6 monthly doses of 0.3, 1, or 2 mg Zimura/ARC1905 in combination with 0.5 mg Lucentis [165].